永新光學(603297.SH):公司總部及廠區搬遷
格隆匯6月29日丨永新光學(603297.SH)公佈,公司因經營發展需要,擬於近期將位於寧波市國家高新區明珠路的公司總部和廠區搬遷至寧波市國家高新區木槿路廠區。該事項已經公司第六屆董事會第二十次會議審議通過。
公司於2017年開始建設的木槿路廠區的廠房主體已建設完成,處於內部裝修階段,其中,募投項目計劃於2020年年底達到預定可使用狀態。根據公司經營管理的實際需要,擬將公司總部及明珠路廠區部分產能逐步搬遷至木槿路廠區,實現辦公管理歸集一處,有利於整合資源、降低成本、提升經營效率,本次搬遷不會對公司生產經營構成重大影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.